These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34528830)

  • 1. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
    Zeng FL; Chen JF
    Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases.
    Zhao Q; Chen Y; Du S; Yang X; Chen Y; Ji Y; Zeng Z
    Cancer Biol Ther; 2021 Mar; 22(3):175-183. PubMed ID: 33722163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in cholangiocarcinoma.
    Beri N
    Immunotherapy; 2023 May; 15(7):541-551. PubMed ID: 37096964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
    Dermime S; Merhi M; Merghoub T
    Front Immunol; 2021; 12():781872. PubMed ID: 34745152
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
    Yan C; Richmond A
    Mol Cancer; 2021 Nov; 20(1):146. PubMed ID: 34758832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
    Hewitt DB; Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting FGFR2 in advanced cholangiocarcinoma: an interview with Arndt Vogel.
    Vogel A
    Future Oncol; 2020 Oct; 16(30):2373-2374. PubMed ID: 33048580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
    Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
    Front Immunol; 2022; 13():943066. PubMed ID: 36159865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
    Naganuma A; Sakuda T; Murakami T; Aihara K; Watanuki Y; Suzuki Y; Shibasaki E; Masuda T; Uehara S; Yasuoka H; Hoshino T; Kudo T; Ishihara H; Ogawa T; Kitamoto Y; Ogawa A
    Intern Med; 2020 Sep; 59(18):2261-2267. PubMed ID: 32536644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
    Xu Y; Fu Y; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():2023. PubMed ID: 33123120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.
    Lei Z; Ma W; Si A; Zhang Y; Yang F; Yu Q; Tang H; Xiao Q; Zhou J; Wang K; Tang Y; Han T; Yin G; Chen J; Liu X; Zhao H; Yu D; Luo T; Wang Q; Yan M; Mao X; Li J; Wang K; Li J; Zeng Y; Ding D; Chen T; Wu X; Xia Y; Wang K; Guo W; Zhu G; Gao S; Hüser N; Lau WY; Song T; Cheng S; Shen F; Cheng Z
    Aliment Pharmacol Ther; 2023 Sep; 58(6):611-622. PubMed ID: 37349908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
    Shek D; Read SA; Akhuba L; Qiao L; Gao B; Nagrial A; Carlino MS; Ahlenstiel G
    Immunotherapy; 2020 May; 12(7):513-529. PubMed ID: 32378480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
    Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
    Front Immunol; 2021; 12():744571. PubMed ID: 34603331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.